FY2025 EPS Estimates for GH Research Lifted by HC Wainwright

GH Research PLC (NASDAQ:GHRS) – Equities researchers at HC Wainwright increased their FY2025 earnings per share (EPS) estimates for GH Research in a research report issued on Monday, July 14th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings per share of ($0.85) for the year, up from their prior forecast of ($0.88). HC Wainwright currently has a “Buy” rating and a $40.00 target price on the stock. The consensus estimate for GH Research’s current full-year earnings is ($0.80) per share.

GH Research (NASDAQ:GHRS) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.19) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.61) by $0.42.

GHRS has been the topic of a number of other research reports. Wall Street Zen raised GH Research from a “sell” rating to a “hold” rating in a research note on Saturday, July 5th. Guggenheim decreased their price objective on GH Research from $32.00 to $29.00 and set a “buy” rating on the stock in a research note on Friday, May 9th. Cantor Fitzgerald assumed coverage on GH Research in a research note on Wednesday, June 4th. They set an “overweight” rating and a $25.00 price objective on the stock. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $39.00 price objective on shares of GH Research in a research note on Tuesday, June 24th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $32.00.

GH Research Stock Up 8.1%

Shares of GHRS stock opened at $17.29 on Wednesday. GH Research has a fifty-two week low of $6.00 and a fifty-two week high of $20.50. The stock has a market cap of $899.60 million, a P/E ratio of -21.89 and a beta of 0.96. The business has a fifty day simple moving average of $12.72 and a 200-day simple moving average of $11.30.

Institutional Trading of GH Research

A number of hedge funds have recently added to or reduced their stakes in the business. RA Capital Management L.P. boosted its stake in GH Research by 3.9% in the 1st quarter. RA Capital Management L.P. now owns 6,944,648 shares of the company’s stock worth $76,599,000 after buying an additional 257,959 shares during the last quarter. Lynx1 Capital Management LP boosted its stake in GH Research by 15.8% in the 4th quarter. Lynx1 Capital Management LP now owns 4,858,994 shares of the company’s stock worth $34,013,000 after buying an additional 663,100 shares during the last quarter. Cormorant Asset Management LP boosted its stake in GH Research by 238.8% in the 1st quarter. Cormorant Asset Management LP now owns 2,009,482 shares of the company’s stock worth $22,165,000 after buying an additional 1,416,439 shares during the last quarter. Jefferies Financial Group Inc. acquired a new stake in GH Research in the 1st quarter worth about $8,272,000. Finally, Alyeska Investment Group L.P. acquired a new stake in GH Research in the 1st quarter worth about $5,018,000. 56.90% of the stock is owned by institutional investors and hedge funds.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).